Evidence map›Paper›PMID 32143717›Full record

ReviewCell communication and signaling : CCS2020

The (pro)renin receptor: a novel biomarker and potential therapeutic target for various cancers.

Juan Wang, Akira Nishiyama, Makoto Matsuyama, Zhiyu Wang, Ying Yuan

Abstract readReviewVideo-Audio Media
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell communication and signaling : CCS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. The (pro)renin receptor as a pharmacological target in cardiorenal diseaes.Hypertension research : official journal of the Japanese Society of Hypertension · 2023
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Synonymous variants in theFrontiers in neurology · 2023
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Renin-angiotensin system and cancer: epidemiology, cell signaling, genetics and epigenetics.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Juan WangDepartment of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. wangjuan2@zju.edu.cn.ORCID 0000-0002-8476-407X
Akira NishiyamaDepartment of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Makoto MatsuyamaDivision of Molecular Genetics, Shigei Medical Research Institute, Okayama, Japan.
Zhiyu WangDepartment of Immuno-oncology, Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, China.
Ying YuanDepartment of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. yuanying1999@zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe (pro) renin receptor ((P)RR) plays important roles in various pathways, such as the Wnt/β-catenin, renin-angiotensin system (RAS), MAPK/ERK and PI3K/AKT/mTOR pathways, that are involved in a wide range of physiological and pathological processes incorporating the tumorigenesis. However, our knowledge about (P) RR was mostly limited to its roles in cardiovascular and renal physiological functions and diseases. In the past 5 years, however, compelling evidence has revealed that (P) RR is aberrantly expressed in and contributes to the development of various cancers by different means. For instance, (P) RR was recently demonstrated to induce the oncogenesis of pancreatic, colorectal and brain cancers via the Wnt signaling, while promote the endometrial cancer and glioblastoma through the RAS.

methodsCombining with the deep analysis of big data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases, this review updates and summarizes the recent studies about the newly recognized roles of (P) RR in the pathophysiological processes of cancer development and its detailed functions through related pathways, as well as the novel research progress of (P) RR in related fields including the development and application of soluble (P) RR detection kit and monoclonal (P) RR antibody.

resultsThis review provides an overview of the essential roles of (P) RR in the tumorigenesis and progression of various cancers and offers a translational outlook for the future research and clinical practices.

conclusion(P) RR in the tumor tissues and/or body fluids of patients may be a novel and promising biomarker and potential therapeutic target for diagnosis, treatment and prognosis prediction in various cancers. Video Abstract.

Indexed as

Biomarkers, TumorCarcinogenesisCell Line, TumorFemaleHumansMaleMiddle AgedNeoplasmsProrenin ReceptorReceptors, Cell SurfaceSignal TransductionVacuolar Proton-Translocating ATPasesATP6AP2 protein, humanBiomarkers, TumorProrenin ReceptorReceptors, Cell SurfaceVacuolar Proton-Translocating ATPasesBiomarkerCancerCancer targeted therapy(Pro) renin receptorRASWnt/β-catenin signaling pathway

Identifiers

PMID32143717
PMCPMC7060546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.